Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacitidine + lenalidomide
- Development stage
- Phase 3
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Subcutaneous, Intravenous, Oral
01
Overview
Azacitidine + lenalidomide is a combination therapy used primarily in the treatment of higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). Azacitidine is a DNA methyltransferase inhibitor that works by incorporating into DNA and RNA, leading to hypomethylation of DNA and direct cytotoxicity to abnormal hematopoietic cells. Lenalidomide is an immunomodulatory agent derived from thalidomide; it exerts its effects by modulating cytokine production, enhancing T cell and natural killer cell activity, inhibiting angiogenesis, and promoting the degradation of specific transcription factors via cereblon-mediated ubiquitination. The combination leverages non-overlapping mechanisms—epigenetic modification by azacitidine and immune modulation plus direct anti-tumor activity by lenalidomide—to improve clinical outcomes in patients with high-risk hematologic malignancies[1][2][4][6].
- Brand names
- Vidaza + Revlimid
- Other names
- 5-azacytidineCC-5013CC5013CC 5013
02
Targets
CRBN (Cereblon)DNMT1 (DNA (cytosine-5)-methyltransferase 1)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on azacitidine + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacitidine + lenalidomide.